Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02063997 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 248
- Enrollment target
NCT02063997: Completed Phase 2 study, sponsored by Gilead Sciences.
NCT02063997 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 248 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02063997, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 248 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether arhalofenate is effective in preventing flares and reducing serum uric acid in gout patients.
Interventions
- DRUG Placebo
- DRUG Colchicine 0.6 mg
- DRUG Arhalofenate 600 mg
- DRUG Allopurinol 300 mg
- DRUG Arhalofenate 800 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
What the finished NCT02063997 record still lists
NCT02063997 is an interventional study that assigns participants to a tested intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (86% higher).
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT02063997 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02063997 about?
NCT02063997 is a clinical study titled "Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients". The purpose of this study is to determine whether arhalofenate is effective in preventing flares and reducing serum uric acid in gout patients.
What is the current status of trial NCT02063997?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 248 participants. The study started on 2014-03. Estimated completion is 2015-01.
What interventions are being tested in trial NCT02063997?
The interventions under investigation include: Placebo (DRUG), Colchicine 0.6 mg (DRUG), Arhalofenate 600 mg (DRUG), Allopurinol 300 mg (DRUG), Arhalofenate 800 mg (DRUG).
Who is sponsoring clinical trial NCT02063997?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02063997's enrollment target sits among peer trials
248 234th of 2000 higher than 1,767 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04577911 · 248 participants
How is Social Connection Represented in the Brain?
- NCT04777994 · 248 participants · Phase 1
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NCT04792489 · 248 participants · Phase 2
DALY II USA/ MB-CART2019.1 for DLBCL
- NCT04830137 · 248 participants · Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia